Discusses the use of alpha-difluoromethylornithine (DFMO) in reducing colorectal mucosal polyamine contents in patients with colon polyps. DFMO as an inhibitor of carcinogenesis in experimental animal models; Activity in preventing carcinogen-induced epithelial cancers; Doses that would deplete target tissue levels of polyamines in humans; More.